VolitionRx Limited Schedules Third Quarter 2017 Earnings Conference Call and Business Update
Conference call to take place Friday, November 10, 2017 at 8:30 am Eastern time
ISNES, Belgium, Nov. 2, 2017 /PRNewswire/ -- VolitionRx Limited (NYSE American: VNRX) today announced it will host a conference call on Friday, November 10 at 8:30 a.m. Eastern time to discuss its financial and operating results from the third quarter of 2017, in conjunction with the filing of its quarterly report on Form 10-Q for the third quarter ended September 30, 2017.
Event: VolitionRx Limited Third Quarter 2017 Earnings and Business Update Conference CallDate: Friday, November 10, 2017Time: 8:30 a.m. Eastern timeU.S. & Canada Dial-in: 1-877-407-9716 (toll free)U.K. Dial-in: 0 800 756 3429 (toll free)Toll/International: 1-201-493-6779Conference ID: 13673016
Cameron Reynolds, President and Chief Executive Officer of Volition, will host the call along with David Vanston, Chief Financial Officer and Scott Powell, Executive Vice President. The call will provide an update on recent developments and Volition's international activities, including details of new and ongoing clinical trials, important events which have taken place in this quarter, and milestones for the remainder of 2017 and into 2018.
To participate in the call, please dial 1-877-407-9716 (toll-free) in the U.S. and Canada, 0-800-756- 3429 (toll-free) in the U.K., and 1-201-493-6779 (toll) internationally. The conference ID number is 13673016.
A live audio webcast of the conference call will also be available on the investor relations page of Volition's corporate website at http://ir.volitionrx.com. In addition, a telephone replay of the call will be available until November 24, 2017. The replay dial-in numbers are 1-844-512-2921 (toll-free) in the U.S. and Canada and 1-412-317-6671 (toll) internationally. Please use replay pin number 13673016.
Volition is a multi-national life sciences company developing simple, easy to use blood-based cancer tests to accurately diagnose a range of cancers. The tests are based on the science of Nucleosomics®, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid - an indication that disease is present.
As cancer screening programs become more widespread, Volition's products aim to help to diagnose a range of cancers quickly, simply, accurately and cost effectively. Early diagnosis has the potential to not only prolong the life of patients, but also to improve their quality of life.
Volition's research and development activities are currently centered in Belgium, with additional offices in London, Texas and Singapore, as the company focuses on bringing its diagnostic products to market first in Europe, then in the U.S. and ultimately, worldwide.
For more information about Volition, visit Volition's website (http://www.volitionrx.com) or connect with us via:
The contents found at Volition's website address, Twitter, LinkedIn, Facebook, and YouTube are not incorporated by reference into this document and should not be considered part of this document. The addresses for Volition's website, Twitter, LinkedIn, Facebook, and YouTube are included in this document as inactive textual references only.
Louise Day, Volitionl.firstname.lastname@example.org+44 (0) 7557 774620
Scott Powell, Volitions.email@example.com+1 (646) 650 1351
Tirth Patel, Edison Advisorstpatel@edisongroup.com+1 (646) 653 7035
Rachel Carroll, Edison Advisorsrcarroll@edisongroup.com+44 (0) 20 3077 5711
Nucleosomics® is a trademark of VolitionRx Limited and its subsidiaries.
SOURCE VolitionRx Limited